Babesia bovis: analysis of and preliminary vaccination studies with a defined infected erythrocyte membrane binding antigen.
Murine monoclonal antibodies (MAB) were produced against the 'beta' fraction of Babesia bovis. A MAB, W11C5, selected on the criterion of its staining of erythrocytes infected with B. bovis, was purified. The antigen identified by MAB W11C5 was extracted from B. bovis infected erythrocytes by affinity chromatography and used in a vaccination trial to test its vaccine efficacy against homologous B. bovis infection in splenectomized calves. The vaccinated group showed significantly different parasitaemias from the control group and it was concluded that the B. bovis antigen 11C5 induced a protective immune response when used as a vaccine. This antigen should be synthesized using recombinant DNA techniques to determine its efficacy and suitability as a commercial vaccine against B. bovis infection.
Goodger
B V
BV
CSIRO Division of Tropical Animal Production, Long Pocket Laboratories, Indooroopilly, Queensland, Australia.
Waltisbuhl
D J
DJ
Wright
I G
IG
White
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000953:Antigens, Protozoan / Q000276:immunology*; D016793:Babesia bovis / Q000276:immunology*; D001404:Babesiosis / Q000517:prevention & control*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D016052:Protozoan Vaccines; D014611:Vaccination / Q000662:veterinary
D000911:Antibodies, Monoclonal; D000953:Antigens, Protozoan; D016052:Protozoan Vaccines